Treatment and management of Helicobacter pylori infection.
Clinical and basic mechanisms of interaction between Helicobacter pylori and its host have been the subject of numerous publications in the past year. Two additional proton pump inhibitors (PPIs), esomeprazole and rabeprazole, have shown effectiveness in H. pylori eradication when combined with amoxicillin and clarithromycin, and esomeprazole has demonstrated its effectiveness with only one daily dose. Other important recent developments worldwide include evidence-based treatment guidelines established at a European consensus meeting, improved accuracy in the urea breath test and the stool antigen test, new recommendations for second-line therapy, and a greater understanding of antimicrobial resistance in treatment failure. In addition, new studies have confirmed that H. pylori infection and use of nonsteroidal anti-inflammatory drugs or aspirin are the major causes of peptic ulcer disease and ulcer bleeding. This paper reviews the results of these studies and their implications for future research.
Go
Mae F
MF
Gastrointestinal Section, Veterans Administration Salt Lake City Health Care System, 500 Foothill Boulevard (111G), Salt Lake City, UT 84148, USA. mae.go@med.va.gov
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D001562:Benzimidazoles / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000382:microbiology; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D064098:Esomeprazole / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D010437:Peptic Ulcer / Q000139:chemically induced / Q000382:microbiology; D064750:Rabeprazole; D013274:Stomach Neoplasms / Q000382:microbiology; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D064750:Rabeprazole; D000658:Amoxicillin; D017291:Clarithromycin; D064098:Esomeprazole